Shopping Cart 0
Cart Subtotal
USD 0

Global Respiratory Complications Therapeutics Market to 2022-Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 9990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 14985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Global Respiratory Complications Therapeutics Market to 2022-Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Summary

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The causes of respiratory disorders vary significantly between indications, with potential causes including infection, vascular damage or dysfunction, aging, environmental stressors such as pollution, and genetic predisposition.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that treat the disease symptoms rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in cystic fibrosis (CF), where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The chronic obstructive pulmonary disease (COPD) and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

The respiratory therapy area contains numerous primary indications, including asthma, COPD, CF and idiopathic pulmonary fibrosis (IPF), which have large prevalent populations. In addition, there are many secondary respiratory conditions that have smaller prevalent populations yet significant unmet clinical needs. This report focuses on these secondary respiratory conditions, particularly pneumonia, respiratory syncytial virus (RSV), pulmonary arterial hypertension (PAH) and tuberculosis (TB).

A major cause of secondary respiratory disease is infections caused by bacteria or viruses. Bacterial infections, such as pneumonia and TB, and viral infections, such as RSV, cause infection of the lungs. The immune system response to these infections causes inflammation that interferes with the ability of the lungs to function. Cardiovascular problems also represent another major cause of respiratory complications. PAH in particular represents a profound risk factor for cardiovascular events in the pulmonary vascular system, including pulmonary embolism.

Overall, there are 843 products in active development in the respiratory complications pipeline. However, this total constitutes many individual indications, most of which are typically relatively small in terms of the number of pipeline products in development. Pneumonia, TB, RSV and PAH are the secondary conditions with the largest development pipelines.

Scope

The respiratory complications market already contains commercially successful products.

Which classes of drug dominate the market?

What additional benefits have newly approved therapies brought to the market?

The respiratory complications pipeline is large, with significant diversity in terms of molecule types and targets.

Which molecular targets appear most frequently in the pipeline?

What are the commercial prospects for the most promising late-stage pipeline products?

The respiratory complications market is forecast to grow from $21.8 billion in 2015 to $30.2 billion in 2022, at a compound annual growth rate of 4.7%.

Which products are forecast to drive this substantial growth?

Will generic competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

What are the leading companies in terms of market share?

Which companies are forecast to experience the greatest growth in market share?

What are the drivers of growth for key companies in the market?

How dependent are the key companies on this disease cluster for revenue?

Reasons to Buy

This report will allow you to

Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which include pneumonia, TB, RSV and PAH.

Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.

Analyze the respiratory complications pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory complications products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.

Identify commercial opportunities in the respiratory complications deals landscape by analyzing trends in licensing and co-development deals.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 10

2.2.1 Pneumonia 10

2.2.2 RSV 10

2.2.3 PAH 11

2.2.4 Tuberculosis 11

2.3 Diagnosis 11

2.3.1 Pneumonia 11

2.3.2 RSV 11

2.3.3 PAH 12

2.3.4 Tuberculosis 12

2.4 Etiology and Pathophysiology 12

2.4.1 Pneumonia 14

2.4.2 RSV 14

2.4.3 PAH 15

2.4.4 Tuberculosis 16

2.5 Epidemiology 17

2.5.1 Pneumonia 17

2.5.2 RSV 18

2.5.3 PAH 18

2.5.4 Tuberculosis 19

2.6 Comorbidities and Complications 20

2.6.1 Pneumonia 20

2.6.2 RSV 20

2.6.3 PAH 20

2.6.4 Tuberculosis 21

2.7 Prognosis 21

2.7.1 Pneumonia 21

2.7.2 RSV 21

2.7.3 PAH 21

2.7.4 Tuberculosis 21

2.8 Treatment 22

2.8.1 Antibiotics 22

2.8.2 Antiviral Drugs 24

2.8.3 Vaccines 25

2.8.4 Antihypertensive drugs 26

2.8.5 Anticoagulants 26

2.8.6 Non-Pharmacological Treatments 27

3 Marketed Products 28

3.1 Overview 28

3.2 Prevnar 13-Pfizer 30

3.3 Synflorix-GlaxoSmithKline 31

3.4 Uptravi-Actelion 32

3.5 Opsumit-Actelion 33

3.6 Eliquis-Bristol-Myers Squibb and Pfizer 34

3.7 Xarelto-Bayer 36

3.8 Synagis-Medimmune 37

3.9 Ventolin-GlaxoSmithKline 38

3.10 Infanrix and Boostrix-GlaxoSmithKline 39

4 Pipeline Landscape Assessment 42

4.1 Overview 42

4.2 Pipeline Development Landscape 42

4.3 Molecular Targets in the Pipeline 45

4.4 Clinical Trials 48

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 48

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 52

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 56

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 59

4.4.5 Conclusion 62

4.5 Assessment of Key Pipeline Products 63

4.5.1 Solithera-Cempra 63

4.5.2 Carbavance (meropenem and vaborbactam) -The Medicines Company 64

4.5.3 Respiratory Syncytial Virus Vaccine-Novavax 65

4.5.4 Conclusion 66

5 Multi-scenario Market Forecast to 2022 67

5.1 Overall Market Size 67

5.2 Generic Penetration 69

5.3 Revenue Forecast by Molecular Target and Drug Category 70

5.3.1 Vaccines 70

5.3.2 G-Protein Coupled Receptors 71

5.3.3 Enzyme Targets 72

5.3.4 Bacterial and Viral Targets 72

5.4 Revenue and Market Share Analysis by Company 73

5.4.1 Pfizer-Prevnar Dominates Respiratory Complications Revenue 77

5.4.2 Actelion-Rapid Growth of PAH Therapies to Create a Strong Market Position 78

5.4.3 GSK-Vast Product Portfolio Will Help Maintain a Strong Market Position 80

5.4.4 Bayer-Despite Limited Portfolio, Xarelto Performance Sufficient to Establish Strong Market Position 81

5.4.5 Bristol-Myers Squibb-Growing Eliquis Revenue to Improve Respiratory Complications Market Position 81

5.4.6 Novavax-Approval of RSV Vaccine Will Help Establish Market Presence 82

5.4.7 United Therapeutics-Variant Treprostinil Formulation to Form Cornerstone of Market Presence 83

6 Company Analysis and Positioning 85

6.1 Company Landscape 86

6.2 Marketed and Pipeline Portfolio Analysis 86

7 Strategic Consolidations 89

7.1 Licensing Deals 89

7.1.1 Deals by Region, Value and Year 89

7.1.2 Deals by Stage of Development and Value 90

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 91

7.1.4 Licensing Deals Valued Above $100m 93

7.2 Co-development Deals 95

7.2.1 Deals by Region, Value and Year 95

7.2.2 Deals by Stage of Development and Value 96

7.2.3 Deals by Molecule Type and Value 97

7.2.4 Co-development Deals Valued Above $100m 99

8 Appendix 101

8.1 Bibliography 101

8.2 All Pipeline Drugs by Phase of Development 106

8.2.1 Discovery 106

8.2.2 Preclinical 123

8.2.3 IND/CTA-filed 165

8.2.4 Phase I 166

8.2.5 Phase II 176

8.2.6 Phase III 186

8.2.7 Pre-registration 192

8.2.8 Unknown 193

8.3 Abbreviations 194

8.4 Methodology 195

8.4.1 Coverage 195

8.4.2 Secondary Research 196

8.4.3 Market Size and Revenue Forecasts 196

8.4.4 Pipeline Analysis 196

8.4.5 Competitive Landscape 197

8.5 Contact Us 197

8.6 Disclaimer 197


List Of Figure

1.2 List of Figures

Figure 1: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015-2022 17

Figure 2: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations (million), 2015-2022 18

Figure 3: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for PAH, 2015-2022 19

Figure 4: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Tuberculosis, 2015-2022 19

Figure 5: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Revenue Forecast, 2015-2022 31

Figure 6: Respiratory Complications Therapeutics Market, Global, Synflorix Revenue Forecast, 2015-2022 32

Figure 7: Respiratory Complications Therapeutics Market, Global, Uptravi Revenue Forecast, 2016-2022 33

Figure 8: Respiratory Complications Therapeutics Market, Global, Opsumit Revenue Forecast, 2015-2022 34

Figure 9: Respiratory Complications Therapeutics Market, Global, Eliquis Revenue Forecast, 2015-2022 35

Figure 10: Respiratory Complications Therapeutics Market, Global, Xarelto Revenue Forecast, 2015-2022 37

Figure 11: Respiratory Complications Therapeutics Market, Global, Synagis Revenue Forecast, 2015-2022 38

Figure 12: Respiratory Complications Therapeutics Market, Global, Ventolin Revenue Forecast, 2015-2022 39

Figure 13: Respiratory Complications Therapeutics Market, Global, Infanrix Revenue Forecast, 2015-2022 40

Figure 14: Respiratory Complications Therapeutics Market, Global, Boostrix Revenue Forecast, 2015-2022 41

Figure 15: Respiratory Complications Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 43

Figure 16: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2017 44

Figure 17: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2017 45

Figure 18: Respiratory Complications Therapeutics Market, Global, Pipeline by Molecular Target, 2017 47

Figure 19: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017 48

Figure 20: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017 49

Figure 21: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017 50

Figure 22: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017 51

Figure 23: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017 52

Figure 24: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 53

Figure 25: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 54

Figure 26: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017 55

Figure 27: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 56

Figure 28: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 56

Figure 29: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 57

Figure 30: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 58

Figure 31: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 59

Figure 32: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017 60

Figure 33: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 60

Figure 34: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017 61

Figure 35: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 62

Figure 36: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Solithera ($m), 2017-2022 64

Figure 37: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Carbavance ($m), 2017-2022 65

Figure 38: Respiratory Complications Therapeutics Market, Global, Revenue for Respiratory Syncytial Virus Vaccine ($m), 2018-2022 66

Figure 39: Respiratory Complications Therapeutics Market, Global, Market Size ($bn), 2015-2022 68

Figure 40: Respiratory Complications Therapeutics Market, Global, Annual Revenue by Generic Products ($m), 2015-2022 70

Figure 41: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Vaccines ($bn), 2015-2022 71

Figure 42: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting G-Protein Coupled Receptors ($bn), 2015-2022 71

Figure 43: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Enzymes ($bn), 2015-2022 72

Figure 44: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs with Bacterial/Viral Targets ($bn), 2015-2022 73

Figure 45: Respiratory Complications Therapeutics Market, Global, Company Analysis Matrix, 2015-2022 74

Figure 46: Respiratory Complications Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 76

Figure 47: Respiratory Complications Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022 77

Figure 48: Respiratory Complications Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022 78

Figure 49: Respiratory Complications Therapeutics Market, Global, Actelion Annual Revenue ($bn), 2015-2022 79

Figure 50: Respiratory Complications Therapeutics Market, Global, GSK Annual Revenue ($bn), 2015-2022 80

Figure 51: Respiratory Complications Therapeutics Market, Global, Bayer Annual Revenue ($bn), 2015-2022 81

Figure 52: Respiratory Complications Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022 82

Figure 53: Respiratory Complications Therapeutics Market, Global, Novavax Annual Revenue ($m), 2018-2022 83

Figure 54: Respiratory Complications Therapeutics Market, Global, United Therapeutics Annual Revenue ($bn), 2015-2022 84

Figure 55: Respiratory Complications Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 85

Figure 56: Respiratory Complications Therapeutics Market, Global, Companies by Type, 2017 86

Figure 57: Respiratory Complications Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2017 87

Figure 58: Respiratory Complications Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Complications, 2015-2022 88


List Of Table

1.1 List of Tables

Table 1: Respiratory Complications Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017 29

Table 2: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Indications, 2017 30

Table 3: Respiratory Complications Therapeutics Market, Global, Synflorix Indications, 2017 31

Table 4: Respiratory Complications Therapeutics Market, Global, Uptravi Indications, 2017 32

Table 5: Respiratory Complications Therapeutics Market, Global, Opsumit Indications, 2017 34

Table 6: Respiratory Complications Therapeutics Market, Global, Eliquis Indications, 2017 35

Table 7: Respiratory Complications Therapeutics Market, Global, Xarelto Indications, 2017 36

Table 8: Respiratory Complications Therapeutics Market, Global, Synagis Indications, 2017 37

Table 9: Respiratory Complications Therapeutics Market, Global, Ventolin Indications, 2017 38

Table 10: Respiratory Complications Therapeutics Market, Global, Infanrix Indications, 2017 40

Table 11: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022 69

Table 12: Respiratory Complications Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022 75

Table 13: Respiratory Complications Therapeutics Market, Global, Licensing Deals Valued above $100m, 2006-2017 93

Table 14: Respiratory Complications Therapeutics Market, Global, Co-development Deals above $100m, 2006-2017 99

Table 15: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Discovery, 2017 106

Table 16: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 123

Table 17: Respiratory Complications Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed, 2017 165

Table 18: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase I, 2017 166

Table 19: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase II, 2017 176

Table 20: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase III, 2017 186

Table 21: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Pre-Registration, 2017 192

Table 22: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Unknown, 2017 193

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Global Respiratory Complications Therapeutics Market to 2022-Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Summary

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The causes of respiratory disorders vary significantly between indications, with potential causes including infection, vascular damage or dysfunction, aging, environmental stressors such as pollution, and genetic predisposition.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that treat the disease symptoms rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in cystic fibrosis (CF), where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The chronic obstructive pulmonary disease (COPD) and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

The respiratory therapy area contains numerous primary indications, including asthma, COPD, CF and idiopathic pulmonary fibrosis (IPF), which have large prevalent populations. In addition, there are many secondary respiratory conditions that have smaller prevalent populations yet significant unmet clinical needs. This report focuses on these secondary respiratory conditions, particularly pneumonia, respiratory syncytial virus (RSV), pulmonary arterial hypertension (PAH) and tuberculosis (TB).

A major cause of secondary respiratory disease is infections caused by bacteria or viruses. Bacterial infections, such as pneumonia and TB, and viral infections, such as RSV, cause infection of the lungs. The immune system response to these infections causes inflammation that interferes with the ability of the lungs to function. Cardiovascular problems also represent another major cause of respiratory complications. PAH in particular represents a profound risk factor for cardiovascular events in the pulmonary vascular system, including pulmonary embolism.

Overall, there are 843 products in active development in the respiratory complications pipeline. However, this total constitutes many individual indications, most of which are typically relatively small in terms of the number of pipeline products in development. Pneumonia, TB, RSV and PAH are the secondary conditions with the largest development pipelines.

Scope

The respiratory complications market already contains commercially successful products.

Which classes of drug dominate the market?

What additional benefits have newly approved therapies brought to the market?

The respiratory complications pipeline is large, with significant diversity in terms of molecule types and targets.

Which molecular targets appear most frequently in the pipeline?

What are the commercial prospects for the most promising late-stage pipeline products?

The respiratory complications market is forecast to grow from $21.8 billion in 2015 to $30.2 billion in 2022, at a compound annual growth rate of 4.7%.

Which products are forecast to drive this substantial growth?

Will generic competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

What are the leading companies in terms of market share?

Which companies are forecast to experience the greatest growth in market share?

What are the drivers of growth for key companies in the market?

How dependent are the key companies on this disease cluster for revenue?

Reasons to Buy

This report will allow you to

Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which include pneumonia, TB, RSV and PAH.

Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.

Analyze the respiratory complications pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory complications products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.

Identify commercial opportunities in the respiratory complications deals landscape by analyzing trends in licensing and co-development deals.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Symptoms 10

2.2.1 Pneumonia 10

2.2.2 RSV 10

2.2.3 PAH 11

2.2.4 Tuberculosis 11

2.3 Diagnosis 11

2.3.1 Pneumonia 11

2.3.2 RSV 11

2.3.3 PAH 12

2.3.4 Tuberculosis 12

2.4 Etiology and Pathophysiology 12

2.4.1 Pneumonia 14

2.4.2 RSV 14

2.4.3 PAH 15

2.4.4 Tuberculosis 16

2.5 Epidemiology 17

2.5.1 Pneumonia 17

2.5.2 RSV 18

2.5.3 PAH 18

2.5.4 Tuberculosis 19

2.6 Comorbidities and Complications 20

2.6.1 Pneumonia 20

2.6.2 RSV 20

2.6.3 PAH 20

2.6.4 Tuberculosis 21

2.7 Prognosis 21

2.7.1 Pneumonia 21

2.7.2 RSV 21

2.7.3 PAH 21

2.7.4 Tuberculosis 21

2.8 Treatment 22

2.8.1 Antibiotics 22

2.8.2 Antiviral Drugs 24

2.8.3 Vaccines 25

2.8.4 Antihypertensive drugs 26

2.8.5 Anticoagulants 26

2.8.6 Non-Pharmacological Treatments 27

3 Marketed Products 28

3.1 Overview 28

3.2 Prevnar 13-Pfizer 30

3.3 Synflorix-GlaxoSmithKline 31

3.4 Uptravi-Actelion 32

3.5 Opsumit-Actelion 33

3.6 Eliquis-Bristol-Myers Squibb and Pfizer 34

3.7 Xarelto-Bayer 36

3.8 Synagis-Medimmune 37

3.9 Ventolin-GlaxoSmithKline 38

3.10 Infanrix and Boostrix-GlaxoSmithKline 39

4 Pipeline Landscape Assessment 42

4.1 Overview 42

4.2 Pipeline Development Landscape 42

4.3 Molecular Targets in the Pipeline 45

4.4 Clinical Trials 48

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 48

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 52

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 56

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 59

4.4.5 Conclusion 62

4.5 Assessment of Key Pipeline Products 63

4.5.1 Solithera-Cempra 63

4.5.2 Carbavance (meropenem and vaborbactam) -The Medicines Company 64

4.5.3 Respiratory Syncytial Virus Vaccine-Novavax 65

4.5.4 Conclusion 66

5 Multi-scenario Market Forecast to 2022 67

5.1 Overall Market Size 67

5.2 Generic Penetration 69

5.3 Revenue Forecast by Molecular Target and Drug Category 70

5.3.1 Vaccines 70

5.3.2 G-Protein Coupled Receptors 71

5.3.3 Enzyme Targets 72

5.3.4 Bacterial and Viral Targets 72

5.4 Revenue and Market Share Analysis by Company 73

5.4.1 Pfizer-Prevnar Dominates Respiratory Complications Revenue 77

5.4.2 Actelion-Rapid Growth of PAH Therapies to Create a Strong Market Position 78

5.4.3 GSK-Vast Product Portfolio Will Help Maintain a Strong Market Position 80

5.4.4 Bayer-Despite Limited Portfolio, Xarelto Performance Sufficient to Establish Strong Market Position 81

5.4.5 Bristol-Myers Squibb-Growing Eliquis Revenue to Improve Respiratory Complications Market Position 81

5.4.6 Novavax-Approval of RSV Vaccine Will Help Establish Market Presence 82

5.4.7 United Therapeutics-Variant Treprostinil Formulation to Form Cornerstone of Market Presence 83

6 Company Analysis and Positioning 85

6.1 Company Landscape 86

6.2 Marketed and Pipeline Portfolio Analysis 86

7 Strategic Consolidations 89

7.1 Licensing Deals 89

7.1.1 Deals by Region, Value and Year 89

7.1.2 Deals by Stage of Development and Value 90

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 91

7.1.4 Licensing Deals Valued Above $100m 93

7.2 Co-development Deals 95

7.2.1 Deals by Region, Value and Year 95

7.2.2 Deals by Stage of Development and Value 96

7.2.3 Deals by Molecule Type and Value 97

7.2.4 Co-development Deals Valued Above $100m 99

8 Appendix 101

8.1 Bibliography 101

8.2 All Pipeline Drugs by Phase of Development 106

8.2.1 Discovery 106

8.2.2 Preclinical 123

8.2.3 IND/CTA-filed 165

8.2.4 Phase I 166

8.2.5 Phase II 176

8.2.6 Phase III 186

8.2.7 Pre-registration 192

8.2.8 Unknown 193

8.3 Abbreviations 194

8.4 Methodology 195

8.4.1 Coverage 195

8.4.2 Secondary Research 196

8.4.3 Market Size and Revenue Forecasts 196

8.4.4 Pipeline Analysis 196

8.4.5 Competitive Landscape 197

8.5 Contact Us 197

8.6 Disclaimer 197


List Of Figure

1.2 List of Figures

Figure 1: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015-2022 17

Figure 2: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations (million), 2015-2022 18

Figure 3: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for PAH, 2015-2022 19

Figure 4: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Tuberculosis, 2015-2022 19

Figure 5: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Revenue Forecast, 2015-2022 31

Figure 6: Respiratory Complications Therapeutics Market, Global, Synflorix Revenue Forecast, 2015-2022 32

Figure 7: Respiratory Complications Therapeutics Market, Global, Uptravi Revenue Forecast, 2016-2022 33

Figure 8: Respiratory Complications Therapeutics Market, Global, Opsumit Revenue Forecast, 2015-2022 34

Figure 9: Respiratory Complications Therapeutics Market, Global, Eliquis Revenue Forecast, 2015-2022 35

Figure 10: Respiratory Complications Therapeutics Market, Global, Xarelto Revenue Forecast, 2015-2022 37

Figure 11: Respiratory Complications Therapeutics Market, Global, Synagis Revenue Forecast, 2015-2022 38

Figure 12: Respiratory Complications Therapeutics Market, Global, Ventolin Revenue Forecast, 2015-2022 39

Figure 13: Respiratory Complications Therapeutics Market, Global, Infanrix Revenue Forecast, 2015-2022 40

Figure 14: Respiratory Complications Therapeutics Market, Global, Boostrix Revenue Forecast, 2015-2022 41

Figure 15: Respiratory Complications Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 43

Figure 16: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2017 44

Figure 17: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2017 45

Figure 18: Respiratory Complications Therapeutics Market, Global, Pipeline by Molecular Target, 2017 47

Figure 19: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017 48

Figure 20: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017 49

Figure 21: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017 50

Figure 22: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017 51

Figure 23: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017 52

Figure 24: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 53

Figure 25: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 54

Figure 26: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017 55

Figure 27: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 56

Figure 28: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 56

Figure 29: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 57

Figure 30: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 58

Figure 31: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 59

Figure 32: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017 60

Figure 33: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 60

Figure 34: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017 61

Figure 35: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 62

Figure 36: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Solithera ($m), 2017-2022 64

Figure 37: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Carbavance ($m), 2017-2022 65

Figure 38: Respiratory Complications Therapeutics Market, Global, Revenue for Respiratory Syncytial Virus Vaccine ($m), 2018-2022 66

Figure 39: Respiratory Complications Therapeutics Market, Global, Market Size ($bn), 2015-2022 68

Figure 40: Respiratory Complications Therapeutics Market, Global, Annual Revenue by Generic Products ($m), 2015-2022 70

Figure 41: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Vaccines ($bn), 2015-2022 71

Figure 42: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting G-Protein Coupled Receptors ($bn), 2015-2022 71

Figure 43: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Enzymes ($bn), 2015-2022 72

Figure 44: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs with Bacterial/Viral Targets ($bn), 2015-2022 73

Figure 45: Respiratory Complications Therapeutics Market, Global, Company Analysis Matrix, 2015-2022 74

Figure 46: Respiratory Complications Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 76

Figure 47: Respiratory Complications Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022 77

Figure 48: Respiratory Complications Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022 78

Figure 49: Respiratory Complications Therapeutics Market, Global, Actelion Annual Revenue ($bn), 2015-2022 79

Figure 50: Respiratory Complications Therapeutics Market, Global, GSK Annual Revenue ($bn), 2015-2022 80

Figure 51: Respiratory Complications Therapeutics Market, Global, Bayer Annual Revenue ($bn), 2015-2022 81

Figure 52: Respiratory Complications Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022 82

Figure 53: Respiratory Complications Therapeutics Market, Global, Novavax Annual Revenue ($m), 2018-2022 83

Figure 54: Respiratory Complications Therapeutics Market, Global, United Therapeutics Annual Revenue ($bn), 2015-2022 84

Figure 55: Respiratory Complications Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 85

Figure 56: Respiratory Complications Therapeutics Market, Global, Companies by Type, 2017 86

Figure 57: Respiratory Complications Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2017 87

Figure 58: Respiratory Complications Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Complications, 2015-2022 88


List Of Table

1.1 List of Tables

Table 1: Respiratory Complications Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017 29

Table 2: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Indications, 2017 30

Table 3: Respiratory Complications Therapeutics Market, Global, Synflorix Indications, 2017 31

Table 4: Respiratory Complications Therapeutics Market, Global, Uptravi Indications, 2017 32

Table 5: Respiratory Complications Therapeutics Market, Global, Opsumit Indications, 2017 34

Table 6: Respiratory Complications Therapeutics Market, Global, Eliquis Indications, 2017 35

Table 7: Respiratory Complications Therapeutics Market, Global, Xarelto Indications, 2017 36

Table 8: Respiratory Complications Therapeutics Market, Global, Synagis Indications, 2017 37

Table 9: Respiratory Complications Therapeutics Market, Global, Ventolin Indications, 2017 38

Table 10: Respiratory Complications Therapeutics Market, Global, Infanrix Indications, 2017 40

Table 11: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022 69

Table 12: Respiratory Complications Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022 75

Table 13: Respiratory Complications Therapeutics Market, Global, Licensing Deals Valued above $100m, 2006-2017 93

Table 14: Respiratory Complications Therapeutics Market, Global, Co-development Deals above $100m, 2006-2017 99

Table 15: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Discovery, 2017 106

Table 16: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 123

Table 17: Respiratory Complications Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed, 2017 165

Table 18: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase I, 2017 166

Table 19: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase II, 2017 176

Table 20: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase III, 2017 186

Table 21: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Pre-Registration, 2017 192

Table 22: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Unknown, 2017 193

To know more information on Purchase by Section, please send a mail to support@kenresearch.com